Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants—a prospective cohort study (RESCUE-TX)
This study was funded by the Medical University of Vienna and an unrestricted grant from AstraZeneca (ESR-21-21585).
Authors
- Roman Reindl‐Schwaighofer (ORCID: https://orcid.org/0000-0002-4419-6282)
- Oliver Helk
- Constantin Aschauer (ORCID: https://orcid.org/0000-0003-3851-734X)
- Rahel Jagoditsch
- Paul Spechtl (ORCID: https://orcid.org/0000-0002-7026-0276)
- Lukas Weseslindtner (ORCID: https://orcid.org/0000-0001-8950-937X)
- Carsten T. Herz (ORCID: https://orcid.org/0000-0003-0888-6275)
- Lukas Raab
- Karin Stiasny (ORCID: https://orcid.org/0000-0002-1902-8674)
- Bernhard Benka (ORCID: https://orcid.org/0000-0002-0913-8677)
- Florina Regele (ORCID: https://orcid.org/0009-0000-8060-4901)
- Andreas Heinzel (ORCID: https://orcid.org/0000-0002-8447-1795)
- Michael Kammer (ORCID: https://orcid.org/0000-0003-4821-9928)
- Thomas Wekerle (ORCID: https://orcid.org/0000-0001-5159-2796)
- Rainer Oberbauer (ORCID: https://orcid.org/0000-0001-7544-6275)
- Robert Straßl (ORCID: https://orcid.org/0000-0002-2157-0382)
- Georg A. Böhmig (ORCID: https://orcid.org/0000-0002-7600-912X)
- Konstantin Doberer (ORCID: https://orcid.org/0000-0002-8036-7042)
- Bianca Reiskopf
- B. Mahr (ORCID: https://orcid.org/0000-0001-5255-381X)
- Karin Hu
Institutions
- Austrian Agency for Health and Food Safety (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- EBioMedicine
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1016/j.ebiom.2024.105417
- Citations
- 5
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.95
Funders
- AstraZeneca
- Universität Wien
- Medizinische Universität Wien